Aurinia Pharmaceuticals
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a v...
Latest News
18 days ago · zacks.com
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings EstimatesAurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.23 per share a year ago.
18 days ago · businesswire.com
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business ProgressEDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025. Net Product Sales: For th.
21 days ago · zacks.com
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to DeclineAurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
22 days ago · zacks.com
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
25 days ago · zacks.com
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 months ago · zacks.com
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock RisesAUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
3 months ago · benzinga.com
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease DrugAurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).
3 months ago · businesswire.com
Aurinia Settles Patent Litigation with TevaEDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.
3 months ago · seekingalpha.com
Aurinia Pharmaceuticals Doubles Down On Its PipelineAurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.
3 months ago · zacks.com
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings EstimatesAurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove AUPH